ערך בספרים למניה: Avenue Therapeutics, Inc. (ATXI)

Avenue Therapeutics attracts leading neurobiologists through a flexible approach to R&D and long-term options. The change in BVPS on the GURU.Markets chart reflects asset dynamics, with the indicator holding at 1.64. The objectivity of these conclusions is ensured by automated data analysis, which, combined with late-stage molecule trials, creates significant potential for operating leverage.

Since Avenue Therapeutics is focused on clinical trials without active commercial products, the book value per common share becomes a key measure of financial stability. The current value of 1.64 reflects net assets minus liabilities, demonstrating to the investor the real value of the ownership stake and the company's margin of safety until its drugs reach the market.